Blog
RSS FeedPosted by Michael Wonder on 02 Nov 2021
Medicare to fund allied health case conferencing
1 November 2021 - New Medicare items will encourage eligible health providers to work together more closely to support the health ...
Posted by Michael Wonder on 26 Oct 2021
Cystic fibrosis medicine added to PHARMAC's options for investment list
27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has ...
Posted by Michael Wonder on 24 Oct 2021
Patient and payer incentives to use patented brand name drugs vs authorised generic drugs in Medicare Part D
18 October 2021 - This cross-sectional study of Medicare formulary and pricing data for quarter 3 of 2020 found that most ...
Posted by Michael Wonder on 12 Oct 2021
European authorities launch HTA network
12 October 2021 - On 29 September, the heads of 19 European HTA authorities met to launch a network for strategic ...
Posted by Michael Wonder on 12 Oct 2021
NICE guidance on inclisiran should be reconsidered
12 October 2021 - Recommendation is premature without data on cardiovascular outcomes. ...
Posted by Michael Wonder on 07 Oct 2021
Ban on negotiating Medicare drug prices under pressure
7 October 2021 - Negotiating Medicare drug prices is a linchpin of President Joe Biden's ambitious health care agenda. ...
Posted by Michael Wonder on 05 Oct 2021
Medicare reverses course on decision to universally cover breakthrough medical devices for 4 years
4 October 2021 - In January 2021, in the waning days of the Trump Administration, the CMS finalised a rule ...
Posted by Michael Wonder on 20 Sep 2021
Medicare bulk billing rates at all time high
18 September 2021 - The latest Medicare data showing that almost nine out of 10 visits to the GP in 2020-21 ...
Posted by Michael Wonder on 11 Sep 2021
Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer disease and mild cognitive impairment
9 September 2021 - In June 2021, the US FDA granted accelerated approval for aducanumab to treat patients with mild cognitive ...
Posted by Michael Wonder on 09 Sep 2021
Biden Administration unveils plan to cut prescription drug prices
9 September 2021 - The Department of Health and Human Services plan supports legislation to empower the government to negotiate Medicare ...
Posted by Michael Wonder on 04 Sep 2021
Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?
3 September 2021 - As Democrats design a way to use the government’s leverage to lower drug prices for seniors, ...
Posted by Michael Wonder on 25 Aug 2021
Don’t meddle with Medicare to save a budget
25 August 2021 - House Democrats this week approved a $3.5 trillion budget framework that has already passed the Senate. ...
Posted by Michael Wonder on 18 Aug 2021
COVID-19 vaccines additional doses: codes & payment
16 August 2021 - The FDA amended the emergency use authorisations for both the Pfizer BioNTech COVID-19 vaccine and the ...
Posted by Michael Wonder on 11 Aug 2021
Medicare expansion and a lower eligibility age are included in Democrats’ $3.5 trillion budget plan
9 August 2021 - There’s no guarantee that these proposals will make it through the full legislative process. ...
Posted by Michael Wonder on 10 Aug 2021
Characterisation of the pharmaceutical risk sharing arrangement process in Catalonia
10 August 2021 - Pharmaceutical risk sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines ...